Winner PK, McAllister P, Chakhava G, et al. - In this randomized clinical trial, researchers sought to assess the effectiveness of and adverse events related to eptinezumab when initiated during a migraine attack. Participants (aged 18 to 75 years) with a migraine history of more than a year and migraine on 4 to 15 days per month in the 3 months prior to screening were treated during a moderate to severe migraine attack. Intravenous administration of eptinezumab, 100 mg (n = 238) or placebo (n = 242) within 1 to 6 hours of the onset of a qualifying moderate to severe migraine. Participants in the study were 476 patients (mean age, 44 years; 84% female). Patients treated with eptinezumab vs placebo had statistically significantly faster pain relief and absence of the most bothersome symptom. Hypersensitivity was the most common treatment-emergent adverse events. There were no treatment-related serious adverse events. Treatment with intravenous eptinezumab vs placebo shortened time to headache and symptom resolution in individuals eligible for preventive migraine therapy who had a moderate to severe migraine attack. The feasibility of administering eptinezumab treatment during a migraine attack and comparing it to alternative treatments are still being investigated.